Compare FMC Corp (FMC) vs UiPath Inc (PATH) Price & Performance

FMC Corporation (FMC) trades at $11.61, up 8.3% today, but remains in a challenging fundamental position with a net income margin of -72.93% and negative ROE of -80.78% for 2025. The company is actively restructuring, securing a $400 million minority investment from Tessenderlo Group and planning a $114 million property sale to reduce its $3.03 billion long-term debt. Technical indicators are bearish, with the stock trading near key support at $11. Recent news highlights progress on its new herbicide, rimisoxafen, including a regulatory submission to the EPA and a partnership with Corteva.

The outlook is cautious. While aggressive debt reduction and new product pipelines offer potential, deep losses and declining revenue pose significant risks. The analyst consensus is mixed (47.6% Buy, 50% Hold) with a $16 price target, suggesting modest upside if turnaround efforts succeed, but high execution risk remains the primary concern for investors.

UiPath (PATH) trades at $11.81, down 1.09% on the day, with a bullish technical signal from moving averages and oscillators. The company reported Q4 2025 EPS of $0.30, beating estimates, but missed in Q1 2026. Revenue growth is strong, reaching $1.43B in 2025, with improving net margins from -58.91% in 2022 to -5.16% in 2025. Analysts maintain a consensus price target of $13.33, suggesting upside potential. Recent news highlights agentic AI advancements with Maestro Case launches.

PATH presents a growth opportunity with robust revenue expansion and margin improvement, though profitability remains negative. Risks include execution on AI monetization and competitive pressures. The stock's current pullback may offer an attractive entry point, supported by bullish analyst sentiment and technical indicators, but investors should weigh near-term earnings volatility against long-term automation trends.